Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 1995-2004

  Hirasawa, Akira ^a,b   Saito Ohara, Fumiko ^a,c   Inoue, Jun ^a,d   Aoki, Daisuke ^b   Susumu, Nobuyuki ^b   Yokoyama, Tetsuji ^e   Nozawa, Shiro ^b   Inazawa, Johji ^a,c   Imoto, Issei ^a,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^e NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA;

ADULT; AGED; APPBP2 GENE; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 17Q; CHROMOSOME ABERRATION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DISEASE COURSE; DNA HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MARKER GENE; ONCOGENE; OVARY ADENOCARCINOMA; PATHOGENESIS; PHENOTYPE; PPM1D GENE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE DOSAGE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASE; PROGNOSIS;

EID: 0037838822     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Holschneider, C. H., and Berek, J. S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol., 19: 3-10, 2000.
3. Serov, S. F., Scully, R. E., and Sobin, L. H. In: International Histologic Classification of Tumors. No. 9. Histologic Typing of Ovarian Tumors, pp. 37-42. Geneva: WHO, 1973.
4. Jenison, E. L., Montag, A. G., Griffiths, C. T., Welch, W. R., Lavin, P. T., Greer, J., and Knapp, R. C. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol. Oncol., 32: 65-71, 1989.
5. Goff, B. A., de la Cuesta, R. S., Muntz, H. G., Fleischhacker, D., Ek, M., Rice, L. W., Nikrui, N., Tamimi, H. K., Cain, J. M., Greer, B. E., and Fuller, A. F., Jr. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol., 60: 412-417, 1996.
6. Behbakht, K., Randall, T. C., Benjamin, I., Morgan, M. A., King, S., and Rubin, S. C. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol. Oncol., 70: 255-258, 1998.
7. Recio, F. O., Piver, M. S., Hempling, R. E., and Driscoll, D. L. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer (Phila.), 78: 2157-2163, 1996.
8. Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Suzuki, M., Sato, I., and Taguchi, K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer (Phila.), 88: 2584-2589, 2000.
9. Omura, G. A., Brady, M. F., Homesley, H. D., Yordan, E., Major, F. J., Buchsbaum, H. J., and Park, R. C. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol., 9: 1138-1150, 1991.
10. Tammela, J., Geisler, J. P., Eskew, P. N., Jr., and Geisler, H. E. Clear cell carcinoma of the ovary: poor prognosis compared with serous carcinoma. Eur. J. Gynaecol. Oncol., 19: 438-440, 1998.
11. Shimizu, Y., Kamoi, S., Amada, S., Hasumi, K., Akiyama, F., and Silverberg, S. G. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features: problems involved in the architectural grading system. Gynecol. Oncol., 70: 2-12, 1998.
12. Vogelstein, B., and Kinzler, K. W. The multistep nature of cancer. Trends Genet., 9: 138-141, 1993.
13. Ried, T., Heselmeyer-Haddad, K., Blegen, H., Schrock, E., and Auer, G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer, 25: 195-204, 1999.
14. Kallioniemi, A., Kallioniemi, O. P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., and Pinkel, D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC), 258: 818-821, 1992.
15. Iwabuchi, H., Sakamoto, M., Sakunaga, H., Ma, Y. Y., Carcangiu, M. L., Pinkel, D., Yang-Feng, T. L., and Gray, J. W. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res., 55: 6172-6180, 1995.
16. Arnold, N., Hagele, L., Walz, L., Schempp, W., Pfisterer, J., Bauknecht, T., and Kiechle, M. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer, 16: 46-54, 1996.
17. Sonoda, G., Palazzo, J., du Manoir, S., Godwin, A. K., Feder, M., Yakushiji, M., and Testa, J. R. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer, 20: 320-328, 1997.
18. Suehiro, Y., Sakamoto, M., Umayahara, K., Iwabuchi, H., Sakamoto, H., Tanaka, N., Takeshima, N., Yamauchi, K., Hasumi, K., Akiya, T., Sakunaga, H., Muroya, T., Numa, F., Kato, H., Tenjin, Y., and Sugishita, T. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology (Basel), 59: 50-56, 2000.
19. Kiechle, M., Jacobsen, A., Schwarz-Boeger, U., Hedderich, J., Pfisterer, J., and Arnold, N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer (Phila.), 91: 534-540, 2001.
20. Watanabe, T., Imoto, I., Kosugi, Y., Ishiwata, I., Inoue, S., Takayama, M., Sato, A., and Inazawa, J. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol. Oncol., 81: 172-177, 2001.
21. Komiyama, S., Aoki, D., Tominaga, E., Susumu, N., Udagawa, Y., and Nozawa, S. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol. Oncol., 72: 342-346, 1999.
22. Fukuda, Y., Kurihara, N., Imoto, I., Yasui, K., Yoshida, M., Yanagihara, K., Park, J. G., Nakamura, Y., and Inazawa, J. CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines. Genes Chromosomes Cancer, 29: 315-324, 2000.
23. Wittwer, C. T., Herrmann, M. G., Moss, A. A., and Rasmussen, R. P. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques, 22: 130-138, 1997.
24. Goff, L. K., Neat, M. J., Crawley, C. R., Jones, L., Jones, E., Lister, T. A., and Gupta, R. K. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the PEL gene in follicular lymphoma. Br. J. Haematol., 111: 618-625, 2000.
25. Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., and Jenkins, R. B. PTEN mutation, EGFR amplification. and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. (Bethesda), 93: 1246-1256, 2001.
26. Westfall, P. H., and Young, S. S. Resampling-based Multiple Testing: Examples and Methods for p-Value Adjustment, New York: John Wiley & Sons Inc., 1993.
27. Westfall, P. H., and Wolfinger, R. D. Closed multiple testing procedures and PROC MULTTEST. SAS Observations. July, 2000.
28. Wu, G. J., Sinclair, C. S., Paape, J., Ingle, J. N., Roche, P. C., James, C. D., and Couch, F. J. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res., 60: 5371-5375, 2000.
29. Barlund, M., Monni, O., Kononen, J., Cornelison, R., Torhorst, J., Sauter, G., Kallioniemi, O. P., and Kallioniemi, A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res., 60: 5340-5344, 2000.
30. Erson, A. E., Biell, B. L., DeMers, S. K., Rouillard, J. M., Hanash, S. M., and Petty, E. M. Overexpressed genes/ESTs and characterization of distinct amplicons on 17q23 in breast cancer cells. Neoplasia, 3: 521-526, 2001.
31. Wu, G. J., Sinclair, C., Hinson, S., Ingle, J. N., Roche, P. C., and Couch. F. J. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. Cancer Res., 61: 4951-4955, 2001.
32. Monni, O., Barlund, M., Mousses, S., Kononen, J., Sauter, G., Heiskanen, M., Paavola, P., Avela, K., Chen, Y., Bittner, M. L., and Kallioniemi, A. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc. Natl. Acad. Sci. USA, 98: 5711-5716, 2001.
33. Varis, A., Wolf, M., Monni, O., Vakkari, M. L., Kokkola, A., Moskaluk, C., Frierson, H., Jr., Powell, S. M., Knuutila, S., Kallioniemi, A., and El-Rifai, W. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res., 62: 2625-2629, 2002.
34. Imoto, I., Yang, Z. Q., Pimkhaokham, A., Tsuda, H., Shimada, Y., Imamura, M., Ohki, M., and Inazawa, J. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res., 61: 6629-6634, 2001.
35. Bulavin, D. V., Demidov, O. N., Saito, S., Kauraniemi, P., Phillips, C., Amundson, S. A., Ambrosino, C., Sauter, G., Nebreda, A. R., Anderson, C. W., Kallioniemi, A., Fornace, A. J., Jr., and Appella, E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet., 31: 210-215, 2002.
36. Okada, S., Tsuda, H., Takarabe, T., Yoshikawa, H., Taketani, Y., and Hirohashi, S. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn. J. Cancer Res., 93: 798-806, 2002.
37. Ho, E. S., Lai, C. R., Hsieh, Y. T., Chen, J. T., Lin, A. J., Hung, M. H., and Liu, F. S. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol. Oncol., 80: 189-193, 2001.
38. Tarkkanen, M., Elomaa, I., Blomqvist, C., Kivioja, A. H., Kellokumpu-Lehtinen, P., Bohling, T., Valle, J., and Knuutila, S. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int. J. Cancer. 84: 114-121, 1999.
39. Bockmühl, U., Schluns, K., Kuchler, I., Petersen, S., and Petersen, 1. Genetic imbalances with impact on survival in head and neck cancer patients. Am. J. Pathol., 157: 369-375, 2000.
40. Ueno, T., Tangoku, A., Yoshino, S., Abe, T., Toshimitsu, H., Furuya, T., Kawauchi, S., Oga, A., Oka, M., and Sasaki, K. Gain of 5p15 detected by comparative genomic hybridization as an independent marker of poor prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 8: 526-533, 2002.
41. Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer, W. E., Vande Woude, G. F., O'Connor, P. M., and Appella, E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. USA, 94: 6048-6053, 1997.
42. Li, J., Yang, Y., Peng, Y., Austin, R. J., van Eyndhoven, W. G., Nguyen, K. C. Q., Gabriele, T., McCurrach, M. E., Marks, J. R., Hoey, T., Lowe, S. W., and Powers, S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet., 31: 133-134, 2002.
43. Zheng, P., Eastman, J., Vande Pol, S., and Pimplikar, S. W. PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proc. Natl. Acad. Sci. USA, 95: 14745-14750, 1998.
44. Couch, F. J., Wang, X. Y., Wu, G. J., Qian, J., Jenkins, R. B., and James, C. D. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res., 59: 1408-1411, 1999.
45. Barlund, M., Forozan, F., Kononen. J., Bubendorf, L., Chen, Y., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., Kallioniemi, O. P., and Kallioniemi, A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. (Bethesda), 92: 1252-1259, 2000.
46. Schwartz, D. R., Kardia, S. L., Shedden, K. A., Kuick, R., Michailidis, G., Taylor, J. M., Misek, D. E., Wu, R., Zhai, Y., Darrah, D. M., Reed, H., Ellenson, L. H., Giordano, T. J., Fearon, E. R., Hanash, S. M., and Cho, K. R. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res., 62: 4722-4729, 2002.
47. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Wash. DC), 237: 178-182, 1987.